Tag: HCC

Introduction and objectives: The development of hepatocellular carcinoma (HCC) is a multi-step process that accumulates genetic and epigenetic alterations, including changes in circular RNA (circRNA). This study aimed to understand the alterations in circRNA expression in HCC development and metastasis and to explore the biological functions of circRNA. Materials and…

Xiao S, Li Q, Jiang J, Huo C, Chen H and Guo M (2023) Rapid Identification of chinese Hamster ovary cell apoptosis and its potential role in process Robustness Assessment. Bioengineering (Basel) 10. doi.org/10.3390/bioengineering10030357 Bryan L, Clynes M and Meleady P (2021) The emerging role of cellular post-translational modifications in…

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS results, a key secondary endpoint of the Phase 2b KEYNOTE-942 study, will be presented at the 2023 American Society of Clinical…

Patients treated with dual immunotherapy-based combination demonstrate sustained clinical benefits after four years vs. chemotherapy alone, with magnitude of benefit more pronounced amongst patient subgroups with high unmet needs Late-breaking data to be presented during the 2023 American Society of Clinical Oncology Annual Meeting PRINCETON, N.J., June 04, 2023–(BUSINESS WIRE)–Bristol…

PRINCETON, N.J.–(BUSINESS WIRE)–Jun 4, 2023– Bristol Myers Squibb (NYSE: BMY) today announced four-year follow-up results from the Phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy compared to four cycles of chemotherapy alone in previously untreated patients with…

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer Details Category: Antibodies Published on Sunday, 04 June 2023 15:16 Hits: 87 Patients treated with dual immunotherapy-based combination demonstrate…

Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced its VP of Business Development, Dr. Sari…

F. Hoffmann-La Roche Ltd Basel, 26 May 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June. Highlights include new data…

Rznomics Inc., a South Korea based biopharmaceutical company specializing in the development of RNA-based gene therapeutics, has received phase 1/2a IND approval from the U.S. FDA for its glioblastoma multiforme (GBM) treatment. RZ-001 initially obtained IND approval for hepatocellular carcinoma (HCC), but Rznomics also found pre-clinical efficacy in GBM models…

Introduction Liver cancer is the third most common cause of cancer death globally with hepatocellular carcinoma (HCC) accounting for the majority of liver cancer.1,2 Early HCC (stage I/II) treatment mainly includes radical surgical resection, radiofrequency ablation and liver transplantation.3,4 However, there is a lack of typical clinical symptoms with early-stage…

The interplay between hepatocellular carcinoma (HCC) cells and the tumor microenvironment is essential for hepatocarcinogenesis, but their contributions to HCC development are incompletely understood. We assessed the role of ANGPTL8, a protein secreted by HCC cells, in hepatocarcinogenesis and the mechanisms through which ANGPTL8 mediates crosstalk between HCC cells and…

HOUSTON, May 16, 2023 /PRNewswire/ — Iterion Therapeutics, a leading biopharmaceutical company dedicated to the development of innovative treatments for cancer, announced today its collaboration in a Phase 1 clinical trial for tegavivint in patients with relapsed or refractory c-Myc-overexpressing large B-cell lymphomas. The first patient has been enrolled to…

Overview of the droplet-based snRandom-seq method for FFPE tissues The main workflow of snRandom-seq is shown in Fig. 1. For single nucleus isolation of FFPE tissues, the areas of interest of banked FFPE tissue block were first selected and placed into tubes. Deparaffinization and rehydration were carried out with standard xylene…

doi: 10.1172/JCI161713. Online ahead of print. Dongmei Gou  1 , Rui Liu  1 , Xiaoqun Shan  1 , Haijun Deng  1 , Chang Chen  2 , Jin Xiang  1 , Yi Liu  1 , Qingzhu Gao  1 , Zhi Li  3 , Ailong Huang  4 , Kai Wang  4 , Ni Tang  1 Affiliations Expand Affiliations 1 Institute for Viral Hepatitis,…

– New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission and clearance in 2H 2023 – – Initial collaboration data with BlueRock and Spark to be presented at ASGCT, validating that Senti’s Gene Circuit enabled cell platform…

Image Credit © PIC4U [stock.adobe.com] Treatment with TPST-1120 demonstrated clinically-meaningful improvements when given in combination with the standard-of-care regimen of atezolizumab (Tecentriq) plus bevacizumab (Avastin) vs atezolizumab and bevacizumab alone for the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC).1 These positive early results come from a…

A new study indicates that an artificial intelligence tool can tremendously improve predictions of whether a nodule will develop cancer, thereby helping identify cancer much earlier in deadly diseases such as lung cancer. Experts at the Royal Marsden NHS foundation trust, the Institute of Cancer Research, London, and Imperial College London…

Background: Epigenetic silencing of tumor suppressor genes (TSGs) is a key feature of oncogenesis in hepatocellular carcinoma (HCC). Liver-targeted delivery of CRISPR-activation (CRISPRa) systems makes it possible to exploit chromatin plasticity, by reprogramming transcriptional dysregulation. Results: Using The Cancer Genome Atlas HCC data, we identify 12 putative TSGs with negative…

Pierre Gholam, MD, professor at Case Western Reserve University School of Medicine in Cleveland, Ohio, discusses his thoughts on a trial (NCT03764293) which evaluated camrelizumab (AiRuiK) and rivoceranib vs sorafenib (Nexavar) in the first-line for patients with unresectable hepatocellular carcinoma (HCC). In the phase 3 study, the PD-1 inhibitor camrelizumab…

doi: 10.3389/fphar.2023.1160445. eCollection 2023. Affiliations Expand Affiliations 1 School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China. 2 Department of Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China. 3 Military Institute of Chinese Materia, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China. 4…

Multi-omics analyses of the ICC samples Following multiregional sampling of primary ICC cases, we performed multi-omics analyses, including genome, transcriptome, proteome, and metabolome analysis. We used 10 (67 samples), 11 (88 samples), 10 (49 samples) and 10 (49 samples) ICC cases for WES, whole-transcriptome sequencing, proteomic analysis, and metabolomic analysis,…

BRISBANE, Calif., April 17, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that new data from its TPST-1120 and TREX1 programs were highlighted in two poster presentations at the 2023 American Association for…

Accumulating evidence demonstrated that nuclear factor erythroid 2-related factor 2 (NRF2) expression plays a crucial role in the proliferation, invasion and metastasis of hepatocellular carcinoma (HCC). However, research on the effect of NRF2 genetic polymorphism on the development of chronic hepatitis B (CHB), HBV-related liver cirrhosis (LC) and HCC is…

COLUMBUS, Ohio – New smart-drug treatment options for pancreatic cancer, immuno-oncology treatments and real-time immune-monitoring strategies are among the research topics to be presented by investigators at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) at…

Genetic mutations can alter how the proteins produced by our genes function and can lead to diseases like cancer. Now researchers have used the gene-editing technology CRISPR/Cas 9 in a less commonly used way, producing liver cancer tumors to better understand the genetic mutations underlying them. Genes contain the information…

AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor”) has applied AlphaFold to an end-to-end AI-powered drug discovery platform (Pharma.AI) that includes a biocomputational engine (PandaOmics) and a generative chemistry platform (Chemistry42), to identify a new drug for a novel target for the…

As the first clinical trial of the drug novobiocin is about to open for patients with cancers carrying BRCA gene mutations, new research at Dana-Farber Cancer Institute shows the drug poses a double threat to tumor cells. As reported March 14 in Nature Communications, the researchers found that in addition…

Review . 2023 Mar 30;S1525-0016(23)00159-4. doi: 10.1016/j.ymthe.2023.03.026. Online ahead of print. Affiliations Expand Affiliations 1 School of Life Science, Chongqing University, Chongqing 400044, P. R. China. 2 School of Life Science, Chongqing University, Chongqing 400044, P. R. China. Electronic address: luozhong918@cqu.edu.cn. Item in Clipboard Review Yingqi Liu et al. Mol Ther….

Vaccitech plc has announced positive topline final data from the HBV002 study, a phase 1b/2a clinical trial of VTP-300 in people with chronic hepatitis B (HBV) infection. Vaccitech is a clinical-stage biopharmaceutical company focused on the development of novel T cell immunotherapeutics to use the immune system to potentially treat…

Using an AI database named AlphaFold, researchers at the University of Toronto and Insilico Medicine, developed a medicine that can potentially treat liver cancer The progress of artificial intelligence in these last few years has not been limited, and AI systems are now doing much more than writing essays, reports…

A representational image of a robot hand showing a DNA sample. — Unsplash/File Apart from artificial intelligence (AI) writing several essays and passing bar exams, it is also capable of treating and detecting different types of cancers, according to a report from Scripps News. Researchers from the University of Toronto…

Researchers at the University of Toronto have developed a potential treatment for liver cancer using artificial intelligence The team applied AlphaFold, an Al-powered protein structure database, to uncover a novel treatment pathway for cancer. The creation of the potential drug was accomplished in just 30 days, and the Al system…

1. Introduction Fusarium fungi are world-wide producers of a range of mycotoxins. Deoxynivalenol (DON) belonging to the group B trichothecenes, is one of the most prevalent food-associated mycotoxins mainly produced by Fusarium graminearum and Fusarium culmorum, and frequently contaminates cereals and cereal products [1,2]. Almost half of a total of…

AI technologies invented by scientists at the University of British Columbia and B.C. Cancer has succeeded in discovering a previously-unknown treatment pathway for an aggressive form of liver cancer, designing a new drug to treat it in the process. The team also deployed AI to determine a patient’s life expectancy, by…

Artificial Intelligence has developed a treatment for cancer in just 30 days. Researchers at the University of Toronto, along with Insilico Medicine, used an AI drug discovery platform called Pharma.AI to create a potential treatment for hepatocellular carcinoma (HCC), the most common type of primary liver cancer. According to the…

Artificial intelligence has developed a cure for an aggressive form of cancer in just 30 days and has shown that it can predict patient survival using doctors’ records. The hacks were implemented through separate systems, but they show how the use of powerful technology goes beyond the creation of images…

21 March 2023 Artificial intelligence has developed a cancer treatment in 30 days. AI has developed a treatment for liver cancer In a new study, researchers at the University of Toronto worked with Insilico Medicine to develop a potential treatment for hepatocellular carcinoma (HCC) – an aggressive form of liver…

Researchers at the University of Toronto, along with Insilico Medicine, have developed a potential treatment for hepatocellular carcinoma (HCC) using an artificial intelligence (AI) drug discovery platform called Pharma.AI. HCC is the most common type of liver cancer and occurs when a tumor grows on the liver. The researchers applied…

Claiming that artificial intelligence can do it all might sound far-fetched at the moment, but with the right training, AI tools could unlock answers in avenues that have plagued humanity for the longest time, including disease management and prevention. An artificial intelligence tool was able to develop a treatment for…

Artificial Intelligence has developed a treatment for cancer in just 30 days and can predict a patient’s survival rate. In a new study published in the journal Chemical Science, researchers at the University of Toronto along with Insilico Medicine developed a potential treatment for hepatocellular carcinoma (HCC) with an AI…

A groundbreaking study published in the journal Chemical Science reveals that artificial intelligence (AI) has successfully created a cancer treatment in merely 30 days while also predicting patient survival rates. Researchers from the University of Toronto and Insilico Medicine collaborated to develop a potential treatment for hepatocellular carcinoma (HCC), the…

Artificial intelligence has developed a treatment for an aggressive form of cancer in just 30 days and demonstrated it can predict a patient’s survival rate using doctors’ notes. The breakthroughs were performed by separate systems, but show how the powerful technology’s uses go far beyond the generation of images and…

Skullcap (Scutellaria barbata) has impressive antitumor properties, making it a potential treatment for chronic disease, in part due to its active ingredient scutebarbatine A. Story at a Glance Skullcap (Scutellaria barbata) is a traditional Chinese medicine (TCM) plant known in China as banzhilian. Researchers used DNA sequencing to uncover how…

I was trained in cell biology and biophysics and, as I was often reminded by study section reviewers, I am “not a cancer biologist”. My closest collaborator, the cell biologist Gunter Blobel6, with whom I had worked for 25 years, encouraged me to leap off in this new direction, building upon…

ADC Therapeutics SA 2022 Annual Report Table of Contents Letter to Shareholders Business Update Financial Review Corporate Governance Report from the Auditor on the Consolidated IFRS Financial Statements Consolidated IFRS Financial Statements for the Year Ended December 31, 2022 Report from the Auditor on the Statutory Financial Statements of ADC…

Richard Finn, MD Professor of Medicine Department of Medicine Division of Hematology/Oncology David Geffen School of Medicine at UCLA Los Angeles, CA Targeted OncologyTM: How have treatment options advanced for patients with hepatocellular carcinoma (HCC) in recent years? FINN: There has been a lot of progress in HCC. Historically speaking,…

R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, CA Cancer J. Clin 72 (2022). doi.org/10.3322/caac.21708 J.M. Llovet, F. Castet, M. Heikenwalder, M.K. Maini, V. Mazzaferro, D.J. Pinato, E. Pikarsky, A.X. Zhu, R.S. Finn, Nat. Rev. Clin. Oncol 19, 151–172 (2022). doi.org/10.1038/s41571-021-00573-2 Article  CAS  PubMed  Google Scholar  J.M. Llovet, T. De Baere, L. Kulik,…

Artificial intelligence designed a new cancer drug in just 30 days. (Getty) Artificial intelligence (AI) designed a potential treatment for an aggressive cancer which kills 700,000 people a year and it took just 30 days. University of Toronto researchers worked with Insilico Medicine to develop potential treatment for hepatocellular carcinoma…

. 2023 Mar;11(3):e006648. doi: 10.1136/jitc-2022-006648. Affiliations Expand Affiliations 1 Department of Hepatic Surgery and Liver Transplantation Center, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. 2 Department of Biotherapy Center, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. 3 Department of Hepatic Surgery and Liver Transplantation…

Backgrounds Secondary to war wounds, surgery, trauma, etc., wound healing depends on the continuous proliferation of fibroblasts and collagen synthesis in the dermis.1,2 Skin scarring is considered as a natural outcome of the wound repair process. The incidence of scars after skin burns, trauma, and operations can be as high…

Received: 9 February 2023 / Revised: 4 March 2023 / Accepted: 6 March 2023 / Published: 9 March 2023 Round 1 Reviewer 1 Report In this paper, they reviewed the role of a long non-coding RNA, H19, in liver cancer. H19 is a lncRNA, which has been extensively studied. Multiple…

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Exelixis, Inc. (Nasdaq: EXEL) today announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS). CONTACT-03 evaluated cabozantinib (CABOMETYX®) in combination with atezolizumab versus cabozantinib alone in patients with locally…

February 28, 2023 6:45 am ET RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-641 and KEYNOTE-789. Merck is discontinuing the Phase 3 KEYNOTE-641 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with…

Circulating cell-free DNA (cfDNA) is a noninvasive substitute to liver biopsy for hepatocellular carcinoma (HCC) molecular profiling. This study aimed to use cfDNA to investigate copy number variation (CNV) in the BCL9 and RPS6KB1 genes and its impact on prognosis in HCC. Real-Time Polymerase Chain Reaction was used to determine…

1 Introduction Cancer is one of the world’s most serious threats to human health, with high morbidity and mortality rates, and according to the latest global data, 9.96 million patients will die from cancer in 2020 (1). Cancer is a genetic abnormal disease triggered by a long-term combination of multiple…

Register for FREE to listen to this article Thank you. Listen to this article using the player above. ✖ Want to listen to this article for FREE? Complete the form below to unlock access to ALL audio articles. The rise of artificial intelligence (AI) is beginning to…

Note: In 2023, some HBC workshops will be taught in person and others will be online via Zoom. ONLINE Workshop dates and times: Friday, March 3rd 2023: 9:30 AM – 12 PM Tuesday, March 7th 2023: 9:30 AM – 12 PM Friday, March 10th 2023: 9:30 AM – 12 PM…

“Most gastric cancers go undetected until an advanced stage, at which point the five-year survival rate is just 6%, one of the lowest across cancer types,” said Dr. Sun Young Rha, director and professor of medical oncology in the Department of Internal Medicine, Songdang Institute for Cancer Research, Yonsei University…

Early detection (pancreatic cancer) cfMeDIP-seq, 5hmC sequencing LR elastic-net Hierarchical clustering, t-SNE, LR with elastic-net penalization Methylation (5mC-5hmC) 208 (72/136) 24-feature 5mC, 27-features 5hmC, 51-features combined model SML, UML Combined 5mC and 5hmC AUC of 0.997 (sensitivity 0.938, specificity 0.955) Median total reads: 17.4 M, 0.8 nonduplicate mapping rate pms.cd120.com/PDAC/index.html…

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced three-year (36.5 months minimum; 44.0 months median) follow-up results from the Phase 3 CheckMate -9ER trial, demonstrating sustained survival and response rate benefits with the…

Infectious diseases, believed to be a thing of the past only a few decades ago owing to the discovery of antibiotics, have resurfaced as an area of active research with the rampant spread of antimicrobial resistance and evolving viruses. Caused by pathogens ranging in size from viruses to worms that…

Genoscience Pharma has announced that its lead candidate, ezurpimtrostat, a PPT-1 (Palmitoyl Protein Thioesterase-1) inhibitor, has been granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC).  ODD qualifies ezurpimtrostat for a potential seven years of market exclusivity after approval….

Introduction Lymphoma, a cancer characterized by a malignant tumor of the immune system that originates in the lymph nodes or lymphoid tissue, is one of the most common cancers worldwide. According to GLOBOCAN, the incidence of non-Hodgkin lymphoma (NHL) in both males and females ranked top ten among all cancers…

DeltaWorks/Pixabay A major artificial intelligence (AI) breakthrough occurred that may herald the start of a new era in drug discovery that may completely revamp biotechnology, pharmaceutical, healthcare, and life sciences industries. Scientists have broken new ground with the AI discovery of a novel drug candidate for liver cancer in just…

A new study uses AlphaFold to identify a potential new treatment for liver cancer The application of AlphaFold in identifying potential liver cancer drugs has been making waves in the medical community. A new study published in Chemical Science, “AlphaFold Accelerates AI-Powered Drug Discovery: Efficient Discovery of a Novel Small…

Of the thousands of diseases that affect humans, treatments exist for only a handful. This lack of available therapeutics and efficiency in drug discovery and development processes is poised for transformation with the advent of artificial intelligence (AI). AlphaFold’s phenomenal success in predicting protein structures for the entire human genome…

doi: 10.3389/fonc.2022.1025192. eCollection 2022. Affiliations Expand Affiliations 1 Department of Oncology, Wuhan Third Hospital, Wuhan, Hubei, China. 2 North Sichuan Medical College, Nanchong, Sichuan, China. 3 Department of Thoracic Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China. 4 Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of…

New Delhi: An international team of scientists has discovered five new meteorites, including one that weighs a whopping 7.6 kilograms from Antarctica. According to the researchers, including those from the Field Museum, Chicago, and the University of Chicago, out of the roughly 45,000 meteorites retrieved from Antarctica over the past…

–To Date, Four Patients Are Now Cancer Free Out of 23 Evaluable– –No Serious Adverse Events Related to Cancer Vaccine Reported, While Adverse Events Continue to be Limited to Grades 1 and 2– –Planning Underway for Potentially Registrational Clinical Trial– PLYMOUTH MEETING, Pa., Dec. 14, 2022 /PRNewswire/ — Geneos Therapeutics, a…

Among individuals who have received COVID-19 vaccines, younger people, females, and those who got the second dose of the Moderna COVID-19 vaccine report more side effects from COVID-19 vaccines that may have led to moderate and severe limitations, according to a recent paper (Front Public Health 2022; doi: 10.3389/fpubh.2022.975781). These…

NEW YORK – A Chinese research team has shown that their method for profiling mutation and DNA methylation patterns in circulating cell-free DNA (cfDNA) can detect hepatocellular carcinoma (HCC) liver cancer cases. “[W]e developed the Mutation Capsule Plus (MCP) technology, supporting parallel profiling of mutations and methylation changes (MCP profiling)…

The following discussion and analysis of our financial condition and results of operations This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those discussed in forward-looking statements. Factors that might cause a difference include, but are not limited to, those discussed above…

Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 380, 1450–1462 (2019). CAS  PubMed  Article  Google Scholar  Affo, S., Yu, L. X. & Schwabe, R. F. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu. Rev. Pathol. 12, 153–186 (2017). CAS  PubMed  Article  Google Scholar  Mederacke, I. et al….

. 2022 Sep 14;2022:3242482. doi: 10.1155/2022/3242482. eCollection 2022. Affiliations Expand Affiliation 1 College of Clinical Medicine, Guizhou Medical University, Guiyang, 550000 Guizhou, China. Item in Clipboard Xing Wang et al. Stem Cells Int. 2022. Show details Display options Display options Format AbstractPubMedPMID . 2022 Sep 14;2022:3242482. doi: 10.1155/2022/3242482. eCollection 2022. Affiliation…

Introduction Multiple myeloma is a B-cell malignancy characterized by the malignant proliferation of clonal plasma cells in bone marrow,1 It is the second most common hematological malignancy after lymphoma.2 The age-standardised rate (ASR) of multiple myeloma incidence was 1·78 (95% UI 1·69-1·87) per 100 000 people globally and mortality was…

As an important carrier of material and energy metabolism, the ordinated modulation of organelle-associated molecules are vital for proper cellular and systemic functions. For example, sterol-regulatory element binding proteins (SREBPs), located on the surface of the endoplasmic reticulum (ER), can rapidly sense changes in intracellular lipid levels, modulate the rate…

Chu, B. B. et al. Cholesterol transport through lysosome-peroxisome membrane contacts. Cell 161, 291–306 (2015). CAS  Article  Google Scholar  Luo, J., Yang, H. & Song, B. L. Mechanisms and regulation of cholesterol homeostasis. Nat. Rev. Mol. Cell Biol. 21, 225–245 (2020). CAS  Article  Google Scholar  Luo, J., Jiang, L., Yang,…

doi: 10.3389/fonc.2022.930220. eCollection 2022. Zhenyu Wang  1 , Xiaoxia Chen  1   2 , Lianer Zhou  1 , Xinge Zhao  1 , Chao Ge  1 , Fangyu Zhao  1 , Haiyang Xie  3 , Taoyang Chen  4 , Hua Tian  1 , Hong Li  1 , Jinjun Li  1 Affiliations Expand Affiliations 1 State Key Laboratory of Oncogenes and Related…

Acute lung injury (ALI) is a severe form of sepsis that is associated with a high rate of morbidity and death in critically ill individuals. The emergence of ALI is the result of several factors at work. Case mortality rates might range from 40% to 70%. Researchers have discovered that…

Purpose: Hepatitis B virus (HBV) plays a crucial role in the progression of hepatocellular carcinoma (HCC). It is known that HBV-encoded X protein (HBx) can induce genetic alterations in some oncogenes and that SMAD4 is relevant for the development of some cancers, especially HBV-related HCC. Previously, it has been reported…

Introduction Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, with an increasing global incidence, and a leading cause of cancer-related mortality.1 Although hepatitis B and C virus infections, cirrhosis, alcohol intake, and non-alcoholic fatty liver disease (NAFLD) are the main risk factors contributing to HCC.1,2 Approximately…

According to our new research study on “Genome Editing Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Technology, Application, and End User,” the market is expected to grow from US$ 5.19 billion in 2021 to US$ 16.98 billion by 2028; it is estimated to grow at…

1  array comparative genomic hybridization(1473 times) Neoplasms(306 times) FISH (238 times)CNVs (135 times)MLPA (72 times) 2003 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. 2  array CGH(43 times) Neoplasms(12 times) CNVs (7 times)FISH (3 times)ID (3 times) 2003 Combined array comparative genomic hybridization and…

image: rt-circRNA rtcisE2F is originated from two adjacent genes CYP2C18 and CYP2C19, involves in the binding between m6A E2F6/E2F3 mRNAs and m6A readers IGF2BP2/YTHDF2, and finally promotes the stability of E2F6/E2F3 mRNAs. E2F6 and E2F3 drive the activation of Wnt/β-catenin signaling and the self-renewal of liver TICs. view more  Credit: ©Science…

ABSTRACT Background: Hepatitis C virus (HCV) related liver cirrhosis occurs in about 20% of chronically infected patients over a duration of 10–20 years, and within 5 years approximately 10–20% of these cirrhotic patients will develop hepatocellular carcinoma (HCC). Previous studies report that the X-ray repair cross-complementing group1 gene (XRCC1) is…

Background: Circular RNAs (circRNAs) have been demonstrated to be closely related to the carcinogenesis of human cancer in recent years. However, the molecular mechanism of circRNAs in the pathogenesis of hepatocellular carcinoma (HCC) has not been fully elucidated. We aimed to identify critical circRNAs and explore their potential regulatory network…

Background Primary hyperaldosteronism (PA) is characterized by spontaneous secretion of excessive aldosterone and inhibition of plasma renin activity.1 The pathogenesis of adrenal aldosterone-producing adenoma (APA) involves the abnormal proliferation of adrenal cortex cells and the excessive secretion of aldosterone, accounting for nearly 30% of PA. Excessive secretion of aldosterone can…

Event listing from University of Pittsburgh: Friday, December 10 from 2:00 PM to 3:00 PM Abstract: The advancement of technologies for high-throughput collection of personal data, including environmental, lifestyle, clinical and biomedical data, has inadvertently transformed biology and medicine. Integrating and co-analyzing these different data streams has become the research…

Introduction According to the cancer statistics reported in 2020, hepatocellular carcinoma (HCC) is the main type of Primary Carcinoma of the Liver and the second leading causes of cancer-related death globally, with a five-year survival rate < 20%.1 Currently, surgical resection, a standard therapy for HCC, contributes to the prognosis…

Stochastic Amplicon Ligation. DNA samples for oncology sequencing are typically extracted from FFPE tissues and can have average lengths of less than 500 nt due to accumulated chemical damage [18]. We developed the Stochastic Amplicon Ligation (SAL) method to enzymatically concatenate many short DNA molecules together to utilize the long-read…

Using a temporal multi-omics approach, a team led by scientists from Heidelberg University has identified a protein involved in tumor metastasis that could serve as a new therapeutic cancer target. Metastasis is the leading cause of cancer-related mortality and the mechanistically least well-understood step of the tumor progression cascade. However,…

Footnotes Grant support This work is jointly supported by National Natural Science Foundation of China (82173035, 81802813,82030079, 81972656, 81988101, and 81902401), the National Science and Technology Major Project of China (2018ZX10723204), the Michigan Medicine and Peking University Health Science Center Joint Institute for Translational and Clinical Research (BMU2020JI005), Natural Science…

Introduction Today, malignant tumors (cancer) still severely imperil human health and cause millions of global mortality rates.1,2 Deep-seated solid tumors are challenging to cure by most therapeutic tools, mainly blamed on the complex tumor microenvironment (TME).3,4 Adoptive cell therapy (ACT), as one of the effective immunotherapeutic means for cancer treatment,…